4 completed. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow sevirumab: new trials by email Literature Review of sevirumab trials Research Report on sevirumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) MSL-109, Placebo - HIV Infections, Cytomegalovirus Retinitis | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 209 | 1995-09-01 | 2015-11-17 |
| Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease SDZ MSL-109 - Cytomegalovirus Infections | Phase 1 / Phase 2 | Completed | National Center for Research Resources (NCRR) | 1995-02-01 | 2005-06-24 | |
| A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Sevirumab - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 300 | 2012-10-25 | |
| Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS Sevirumab, Foscarnet sodium, Ganciclovir - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 167 | 2021-11-01 |
Cytomegalovirus Retinitis (3) · HIV Infections (3) · AIDS-Related Opportunistic Infections (2) · Acquired Immunodeficiency Syndrome (2) · Communicable Diseases (1) · Cytomegalovirus Infections (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Infant, Newborn, Diseases (1) · Multiple Acyl Coenzyme A Dehydrogenase Deficiency (1) · Rare Diseases (1) · Virus Diseases (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Johns Hopkins Bloomberg School of Public Health (1) · National Center for Research Resources (NCRR) (1)
United States (2)
Borucki M (1) · Gnann J (1) · Hirsch MS (1) · Pollard RB (1) · Richard J. Whitley (1)
PMID 11919489, PMID 12232843, PMID 12559647, PMID 15498605, PMID 31042791, PMID 9400786